


ASCO GI 2021 にて Nivolumab のバイオマーカーとして 腸内細菌叢の有用性が公表されました

Genomic pathway of gut microbiome to predict efficacy of nivolumab in advanced gastric cancer:
DELIVER trial (JACCRO GC-08)

聖マリアンナ医科大学 砂川 優先生が Oral で発表されました。*Odoribacter* と *Veillonella* が
Nivolumab の効果のバイオマーカーの候補として同定されました
研究参加各位にお礼申し上げます。

Candidate biomarkers for nivolumab response



- An exploratory analysis of genus showed that *Odoribacter* and *Veillonella* were associated with tumor response to Nivo in both cohorts.

PRESENTED AT: Gastrointestinal
Cancers Symposium

Slides are the property
of the author; permission
required for reuse.

PRESENTED BY: Yu Sunakawa

#GI21

Summary of results

- More diverse microbiome was observed in patients with non-PD compared to patients with PD.
- There was no statistically significant pathway to be validated for a primary endpoint under Bonferroni method, however, Bacterial invasion of epithelial cells pathway in the KEGG pathway was associated with clinical outcome of Nivo in both training cohort ($p=0.057$) and validation cohort ($p=0.014$),
✓ Upregulation of the pathway was related to PD at the first evaluation for Nivo treatment.
- An exploratory analysis of genus showed that *Odoribacter* and *Veillonella* were associated with tumor response to Nivo in both cohorts.

PRESENTED AT: Gastrointestinal
Cancers Symposium

Slides are the property
of the author; permission
required for reuse.

PRESENTED BY: Yu Sunakawa

#GI21